Calidi Biotherapeutics Inc CLDI

US Biotechnology

$1.64 ▲ +9.86% (+$0.15)

⬆️ Above Yest. High 🔥 High Short Interest 🗓️ Earnings Next Week

Open $1.93

Prev Close $1.49

Day Range $1.53 – $1.93

52W Range $1.48 – $120.96

Market Cap $28.83M

Beta 1.38

EPS (TTM) $-4.00

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NYSE MKT LLC
Currency	USD
IPO Date	2021-09-10
Shares Out.	19,310,000
Website	calidibio.com/ ↗
Phone	18587949600
Employees	29
Net Income	-$4.1M
Free Cash Flow	-$18.4M
Total Assets	$9.6M
Total Liabilities	$4.7M
Equity	$4.9M

About Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Calidi Biotherapeutics Inc is a publicly traded company under the ticker symbol CLDI on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.